Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo) -- Ignore unavailable to you. Want to Upgrade?

To: Street Walker who wrote (869)	11/17/1998 5:19:00 PM
From: Dr. John M. de Castro	Read Replies (1) \| Respond to of 887

32% return in a few months !! DEPO closed today at 3 and SKYEY at 13 9/16. Assuming that the FDA gives its formal approval to DepoCyt (a virtual certainty), and that DEPO shareholders approve the merger (with SKYEY holding 19% of the stock this is also a virtual certainty) then shareholders in DEPO will receive .292 shares of SKYEY for each share of DEPO. As a result, if SKYEY stock value stays the same as it is today, then DEPO shareholders will receive the SKYE shares valued at $3.96 (that is 13 9/16 X .292). This is a 32% increase above todays market close for DEPO. This return could be even higher if SKYEY continues to increase in value and/or DEPO gets a partner for DepoMorphine or for Depo??. I'd gauge a 32% return in a couple of months as very attractive. John de C